Intranasal Nanoparticles for the Treatment of Depression and Anxiety Disorders
The treatment of central nervous system disorders, such as depression and anxiety, relies on the oral administration of drugs with antidepressant or anxiolytic action. Given the increased incidence of these diseases and the disadvantages of oral drug administration, studies are being performed with...
Main Authors: | Margarida Alberto, Ana Cláudia Paiva-Santos, Francisco Veiga, Patrícia C. Pires |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Engineering Proceedings |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-4591/31/1/72 |
Similar Items
-
Lipid and Polymeric Nanoparticles: Successful Strategies for Nose-to-Brain Drug Delivery in the Treatment of Depression and Anxiety Disorders
by: Margarida Alberto, et al.
Published: (2022-12-01) -
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies
by: Cláudia Pina Costa, et al.
Published: (2021-04-01) -
Intranasal Delivery of Genistein-Loaded Nanoparticles as a Potential Preventive System against Neurodegenerative Disorders
by: Giovanna Rassu, et al.
Published: (2018-12-01) -
An In Vitro Evaluation of the Potential Neuroprotective Effects of Intranasal Lipid Nanoparticles Containing Astaxanthin Obtained from Different Sources: Comparative Studies
by: Joana Torres, et al.
Published: (2023-03-01) -
Nanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs
by: Jéssica L. Antunes, et al.
Published: (2023-03-01)